Noxopharm Limited. ABN 50 608 966 123 Level 20, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067 AUSTRALIA Appendix 4G and Corporate Governance Statement Sydney, 16 October 2026: Innovative biotech company Noxopharm Limited (ASX:NOX) attached the following documents in relation to...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Annual Report to shareholders
- FDA feedback supports SOF-SKN Phase II plans
- Audited Financial Statements
- SOF-SKN to progress to extension study in CLE patients
- Investor Presentation September 2026
Later from Noxopharm
- 2026 AGM Letter of Access, Notice of Meeting and Proxy
- Trading Halt
- Voluntary Suspension
- Noxopharm Successfully Raises $1.5 Million via Placement
- Reinstatement to Quotation
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm